# US 2004/0082067 A1 · Conjugation of biomolecules using diels-alder cycloaddition

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0082067 A1
- Document ID: US20040082067A1
- Status: Published application
- Kind: A1
- Application number: 10/692,411
- Filed: 2003-10-22
- Published: 2004-04-29
- Earliest claimed: 2000-08-09
- Assignees: The Government of the U.S.A. as represented by the Secretary of the Dept. of Hlth. and Human Service
- Inventors: Vince Pozsgay
- Web page: https://patentgrep.com/patent/US20040082067A1

## CPC

- A61K 39/385: Haptens or antigens, bound to carriers
- A61K 39/0275: {Salmonella}
- A61K 39/0283: {Shigella}
- A61K 47/61: the organic macromolecular compound being a polysaccharide or a derivative thereof
- A61K 47/643: {Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]}
- C07K 1/1077: {by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids}
- C07K 16/44: against material not provided for elsewhere {, e.g. haptens, metals, DNA, RNA, amino acids}
- C08B 37/00: Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof (cellulose D21; {microbiological processes C12P})
- C08B 37/0021: {Dextran, i.e. (alpha-1,4)-D-glucan; Derivatives thereof, e.g. Sephadex, i.e. crosslinked dextran}
- C12N 11/10: the carrier being a carbohydrate
- A61K 2039/6037: {Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]}
- A61K 2039/6068: {Other bacterial proteins, e.g. OMP}
- A61K 2039/6081: {Albumin; Keyhole limpet haemocyanin [KLH]}
- A61K 2039/62: {characterised by the link between antigen and carrier}
- A61K 2039/627: {characterised by the linker}
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C08B: POLYSACCHARIDES; DERIVATIVES THEREOF (polysaccharides containing less than six saccharide radicals attached to each other by glycosidic linkages C07H; fermentation or enzyme-using processes C12P19/00; sugar industry C13; production of cellulose D21)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

A method is provided for covalently linking carbohydrates, proteins, nucleic acids, and other biomolecules under neutral conditions, using a Diels-Alder cycloaddition reaction. In an example, activated carbon-carbon double bonds were attached to free amino sites of a carrier protein, and a conjugated diene was attached to a carbohydrate hapten. Spontaneous coupling of the carbohydrate and the protein components under very mild conditions provided glycoconjugates containing up to 37 carbohydrate hapten units per carrier protein molecule. The method is also applicable to the immobilization of biomolecules on gel or solid supports. The conjugated products are useful as immunogens and as analytical and diagnostic reagents.

## Claims

### Claim 1

A method of coupling a first biomolecule to a second biomolecule, comprising:
(a) covalently attaching a diene moiety to the first biomolecule to form a diene component;
(b) covalently attaching a dienophile to the second biomolecule to form a dienophile component; and
(c) contacting the diene component with the dienophile component under conditions that permit a cycloaddition reaction to occur between the components.

### Claim 2

A method of coupling a biomolecule to a gel or solid support, comprising:
(a) covalently attaching a diene moiety to a substrate selected from the group consisting of the biomolecule and the support, to form a diene component;
(b) covalently attaching a dienophile to the substrate not selected in step (a) to form a dienophile component; and
(c) contacting the diene component with the dienophile component under conditions that permit a cycloaddition reaction to occur between the components.

### Claim 3 (depends on 1)

The method of claim 1, wherein the first biomolecule is a polysaccharide and the second biomolecule is a polypeptide.

### Claim 4 (depends on 3)

The method of claim 3 wherein the polysaccharide is selected from the group consisting of bacterial capsular polysaccharides, fragments thereof, and synthetic analogues thereof.

### Claim 5 (depends on 4)

The method of claim 4, wherein the bacterial capsular polysaccharide is selected from the group consisting of capsular polysaccharides of Haemophilus influenzae type b, Neisseria meningitidis, Group B Streptococci, Salmonella typhi, E. coli, Pneumococci.

### Claim 6 (depends on 3)

The method of claim 3 wherein the polypeptide is selected from the group consisting of bacterial toxins, bacterial toxoids, bacterial outer membrane proteins, keyhole limpet hemocyanin, horseshoe crab hemocyanin, edestin, mammalian serum albumins, mammalian gamma-globulins, and IgG-G.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The method of any one of claims 1-6 wherein the dienophile moiety is attached to the biomolecule by contacting the biomolecule with 3-sulfosuccinimidyl 4-maleimidobutyrate.

### Claim 8 (depends on 3, 4, 5, 6)

The method of any one of claims 3-6 wherein the diene moiety is attached to the polysaccharide by glycosylation of trans,trans-hexa-2,4-dien-1-ol with the polysaccharide.

### Claim 9 (depends on 7)

The method of claim 7 wherein one of the biomolecules is a polysaccharide, and the diene moiety is attached to the polysaccharide by glycosylation of trans,trans-hexa-2,4-dien-1-ol with the polysaccharide.

### Claim 10 (depends on 1)

A conjugate of biomolecules prepared by the method of claim 1.

### Claim 11 (depends on 2)

A conjugate of a biomolecule with a solid or gel support, prepared by the method of claim 2.

### Claim 12 (depends on 3, 4, 5, 6)

A conjugate of biomolecules prepared by the method of any one of claims 3-6.

### Claim 13 (depends on 7)

A conjugate of biomolecules prepared by the method of claim 7.

### Claim 14 (depends on 8)

A conjugate of biomolecules prepared by the method of claim 8.

### Claim 15 (depends on 9)

A conjugate of biomolecules prepared by the method of claim 9.

### Claim 16

A conjugate of biomolecules selected from the group consisting of
13
wherein R and R′ are independently H or methyl, or together constitute CH2, CH2CH2, or O; X is CH or N; Y is N, CH═C, or NH—N; and B1 and B2 comprise biomolecules independently selected from the group consisting of polypeptides, carbohydrates, polysaccharides, and nucleic acids, and are optionally attached via a linker.

### Claim 17 (depends on 16)

The conjugate of biomolecules according to claim 16, wherein one of the biomolecules is a polysaccharide.

### Claim 18 (depends on 17)

The conjugate of biomolecules according to claim 17, wherein the polysaccharide is a viral or bacterial polysaccharide.

### Claim 19 (depends on 16)

The conjugate of biomolecules according to claim 16, wherein one of the biomolecules is a polysaccharide and the other biomolecule is a polypeptide.

### Claim 20 (depends on 19)

The conjugate of biomolecules according to claim 19, wherein the polysaccharide is a viral or bacterial polysaccharide.

### Claim 21

An immobilized biomolecule selected from the group consisting of
14
wherein R and R′ are independently H or methyl, or together constitute CH2, CH2CH2, or O; X is CH or N; Y is N, CH═C, or NH—N; one of B1 and B2 comprises a biomolecule selected from the group consisting of polypeptides, carbohydrates, polysaccharides, and nucleic acids and the other of B1 and B2 is a solid or gel support, and B1and B2 are optionally attached via a linker.

### Claim 22 (depends on 10, 11)

A pharmaceutical composition comprising a conjugate according to any one of claims 10, 11, or 16-20, further comprising a pharmaceutically acceptable carrier.

### Claim 23 (depends on 12)

A pharmaceutical composition comprising a conjugate according to claim 12, further comprising a pharmaceutically acceptable carrier.

### Claim 24 (depends on 13)

A pharmaceutical composition comprising a conjugate according to claim 13, further comprising a pharmaceutically acceptable carrier.

### Claim 25 (depends on 14)

A pharmaceutical composition comprising a conjugate according to claim 14, further comprising a pharmaceutically acceptable carrier.

### Claim 26 (depends on 15)

A pharmaceutical composition comprising a conjugate according to claim 15, further comprising a pharmaceutically acceptable carrier.

### Claim 27 (depends on 22)

A method of inducing, in a mammal, antibodies which immunoreact with a polysaccharide, comprising administering to said mammal a composition according to claim 22, wherein one of the biomolecules is a polysaccharide.

### Claim 28 (depends on 23)

A method of inducing, in a mammal, antibodies which immunoreact with a polysaccharide, comprising administering to said mammal a composition according to claim 23.

### Claim 29 (depends on 24)

A method inducing, in a mammal, antibodies which immunoreact with a polysaccharide, comprising administering to said mammal a composition according to claim 24, wherein one of the biomolecules is a polysaccharide.

### Claim 30 (depends on 25)

A method of inducing, in a mammal, antibodies which immunoreact with a polysaccharide, comprising administering to said mammal a composition according to claim 25.

### Claim 31 (depends on 26)

A method of inducing, in a mammal, antibodies which immunoreact with a polysaccharide, comprising administering to said mammal a composition according to claim 26.

### Claim 32 (depends on 27)

An antibody which immunoreacts with a polysaccharide, wherein said antibody is obtained from a mammal, and wherein the production of the antibody by the mammal has been induced by the method of claim 27.

### Claim 33 (depends on 28)

An antibody which immunoreacts with a polysaccharide, wherein said antibody is obtained from a mammal, and wherein the production of the antibody by the mammal has been induced by the method of claim 28.

### Claim 34 (depends on 29)

An antibody which immunoreacts with a polysaccharide, wherein said antibody is obtained from a mammal, and wherein the production of the antibody by the mammal has been induced by the method of claim 29.

### Claim 35 (depends on 30)

An antibody which immunoreacts with a polysaccharide, wherein said antibody is obtained from a mammal, and wherein the production of the antibody by the mammal has been induced by the method of claim 30.

### Claim 36 (depends on 31)

An antibody which immunoreacts with a polysaccharide, wherein said antibody is obtained from a mammal, and wherein the production of the antibody by the mammal has been induced by the method of claim 31.

### Claim 37 (depends on 27)

An antibody, produced by a hybridoma, which immunoreacts with a polysaccharide, wherein nucleic acid sequences encoding said antibody in said hybridoma are obtained from a mammal in which the production of the antibody has been induced by the method of claim 27.

### Claim 38 (depends on 28)

An antibody, produced by a hybridoma, which immunoreacts with a polysaccharide, wherein nucleic acid sequences encoding said antibody in said hybridoma are obtained from a mammal in which the production of the antibody has been induced by the method of claim 28.

### Claim 39 (depends on 29)

An antibody, produced by a hybridoma, which immunoreacts with a polysaccharide, wherein nucleic acid sequences encoding said antibody in said hybridoma are obtained from a mammal in which the production of the antibody has been induced by the method of claim 29.

### Claim 40 (depends on 30)

An antibody, produced by a hybridoma, which immunoreacts with a polysaccharide, wherein nucleic acid sequences encoding said antibody in said hybridoma are obtained from a mammal in which the production of the antibody has been induced by the method of claim 30.

### Claim 41 (depends on 31)

An antibody, produced by a hybridoma, which immunoreacts with a polysaccharide, wherein nucleic acid sequences encoding said antibody in said hybridoma are obtained from a mammal in which the production of the antibody has been induced by the method of claim 31.

### Claim 42 (depends on 32)

A method of inducing passive immunity in a mammal, comprising administering to said mammal an effective amount of an antibody according to claim 32.

### Claim 43 (depends on 37)

A method of inducing passive immunity in a mammal, comprising administering to said mammal an effective amount of an antibody according to claim 37.

### Claim 44 (depends on 12)

A vaccine composition comprising a conjugate according to claim 12, further comprising an adjuvant and a pharmaceutically acceptable carrier.

### Claim 45 (depends on 13)

A vaccine composition comprising a conjugate according to claim 13, further comprising an adjuvant and a pharmaceutically acceptable carrier.

### Claim 46 (depends on 14)

A vaccine composition comprising a conjugate according to claim 14, further comparing an adjuvant and a pharmaceutically acceptable carrier.

### Claim 47 (depends on 15)

A vaccine composition comprising a conjugate according to claim 15, further comprising an adjuvant and a pharmaceutically acceptable carrier.
